title: Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
authors.affiliation: From the Department of Stroke Medicine, Imperial College London, London, United Kingdom (R.V.); Department of Neurology, University of Heidelberg, Heidelberg, Germany (R.V.); and Department of Neurology, Northwestern University, Chicago, IL (S.P.). roland.veltkamp@imperial.nhs.uk.
authors.forename: Roland
authors.initials: R
authors.lastname: Veltkamp
authors.affiliation: From the Department of Stroke Medicine, Imperial College London, London, United Kingdom (R.V.); Department of Neurology, University of Heidelberg, Heidelberg, Germany (R.V.); and Department of Neurology, Northwestern University, Chicago, IL (S.P.).
authors.forename: Shyam
authors.initials: S
authors.lastname: Prabhakaran
mesh_terms: D000328:Adult; D001281:Atrial Fibrillation / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D065427:Factor Xa Inhibitors; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D020521:Stroke / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; D014859:Warfarin; C552171:edoxaban
keywords: atrial fibrillation